RE:RE:RE:ONCY pelareorep + CAR-T therapy as explained by Mayo ClinicBarriers such as tumor heterogeneity and T cell exhaustion have exposed the weaknesses of various mono-immunotherapeutic approaches to GBM, including CAR T cell and checkpoint blockade strategies.
ONCY's pelareorep to (1) dramatically increase CAR-T cell persistence, (2) reverse an immunosuppressive tumor microenvironment (TME) and (3) to overcome the attenuation of antigen escape induced by T-cell immunotherapy is showing to be a significant benefit of this pelareorep + CAR-T immuno-oncology (I/O) combination therapy, particularly after a subsequent intravenous boost of pelareorep is given following the initial dose of pelareorep + CAR-T therapy.
Combining these three (3) complementary strategies, can proffer a rational means of mitigating these barriers and advancing therapeutic successes against GBM, pancreatic cancer and other solid tumors.